Fig. 4From: Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosaSubjective complain during the study. The subjective complain for the safety (a) and efficacy (b) of autologous intravitreal injection of BM-MSCs during the 12-month follow-upBack to article page